CHARLES W. LAPP, M.D.
7421 Carmel Executive Park, Suite 320, Charlotte NC 28226
Tel 704.543-9692 • Fax 704.543.8547
Curriculum Vitae
| Business | Physician and Medical Director, 1995- Hunter-Hopkins Center Medical Consultations Charlotte, North Carolina Founder (1978), Physician (1978-2015 ), and President (1978- 1996) |
|---|---|
| Education | Doctor of Medicine, Albany Medical College Albany, New York 1974 Master of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY 1970 Bachelor of Science, Rensselaer Polytechnic Institute, Troy, NY 1969 |
| Postgraduate Education | Residencies in Internal Medicine and Pediatrics at North Carolina Memorial Hospital, Chapel Hill, NC 1978 Internship at North Carolina Memorial Hospital, Chapel Hill, NC 1974 Externships at Cleveland Clinic Foundation, University of Florida at Gainesville, and Yale University Medical Center |
| Board Certification | Diplomate, American Board of Internal Medicine, 1978 Diplomate, American Board of Pediatrics, 1979 Diplomate, American Board of Independent Medical Examiners, 1997 |
| Fellowships | Fellow, American Academy of Pediatrics, 1986 Fellow, American Academy of Family Physicians, 1987 Fellow, American Academy of Disability Evaluating Physicians, 1996 |
| Honors | Tapped by DHHS Secretary Tommy Thompson, CFS Advisory Committee Cited in Marquis’ Who’s Who and Who’s Who in Medicine, 1996- Duke University Clinical Professor of the Year, 1986 Nominated Doctor of the Year, Raleigh, 1984 Nominated Jaycee Man of the Year, 1983 Richard T. Beebe Scholar of Medicine, 1974 Tau Beta Pi National Engineering Honor Society, 1968 |
| Professional Associations | American Medical Association, 1972-2010 North Carolina Medical Society, 1978-life County Medical Society, 1978-2017 American Academy of Pediatrics, 1976-2002 American Academy of Family Physicians, 1974-2011 American Association for CFS and FM, VP 2001-2003, 1992-life American Pain Society, 1994- American Academy of Disability Evaluating Physicians, 1995-2010 |
| Experience | Reviewer, National Academy of Science/Institute of Medicine, 2014-15 Assistant Consulting Professor at Duke University Division of Community and Family Medicine, 1982-2017 Associate Clinical Professor at University of North Carolina Department of Pediatrics, 1978-1991 Medical Director of The Cheney Clinic, Charlotte, NC, 1991-1995 Board, American Association for Chronic Fatigue Syndrome, 1999-2005 VP, American Association for Chronic Fatigue Syndrome, 2001-2003 Board, American Fibromyalgia Syndrome Association, 1999-2012 Medical Advisor to CFIDS Association of America, 1992-2013 Participant in CDC and NIH CFS workshops Trainer for the CDC and Health Services and Resource Administration Consultant to the Technical Advisory Service for Attorneys, 1979-2002 Founder of Piedmont Medical Associates, PA, 1978 |
| Research | Dr. Lapp has performed clinical research for: Center for Disease Control (Multisite Clinical Assessment of CFS) Pfizer (Lyrica, reboxetine) Hemispherx Biopharma (Ampligen/rintatolimod) Cephalon (Provigil) Schwarz (lacosamide) Sepracor (Lunesta) Eli Lilly (Keftabs, Cymbalta) Ortho McNeill (Axert) Grunenthal Pro Health (Transfer Factor) |
| Articles | Unger, E.R.; Lin, J.-M.S.;Chen, Y.; Cornelius, M.E.; Helton, B.;Issa, A.N.; Bertolli, J.; Klimas, N.G.;Balbin, E.G.; Bateman, L.; Lapp, C.W.,et al., “Heterogeneity in measures of illness among patients with myalgic encephalomyelitis/chronic fatigue syndrome is not explained by clinical practice: a study in seven U.S. specialty clinics,” J. Clin. Med. 2024, 13, 1369.
Lapp CW, “Initiating care of a patient with myalgic encephalopathy/chronic fatigue syndrome,” Frontiers in Pediatrics, 23 Jan 2019, www.frontiersin.org/journal/600 Valdez AR, Hancock AE, Lapp CW, et al, “Estimating prevalence, demographics, and costs of ME/CFS using large scale medical claims data and machine learning,” Frontiers in Pediatrics, 08 Jan 2019, www.frontiersin.org/journal/600 Unger ER, Jin Mann SL, Hao T, Lapp CW, et al., “Multi-site clinical assessment of myalgic encephalomyelitis/chronic fatigue syndrome (MCAM): design and implementation of a prospective/retrospective rolling cohort study,” 01 Jan 2017, Amer J Epidem Unger ER, Jin Mann SL, Brimmer DJ, Lapp CW, Komaroff A, Nath A, “CDC grand rounds: chronic fatigue syndrome – advancing research and clinical education,” 30 Dec 2016, Morbidity and Mortality Weekly Report Strayer D, Stouch BC, et al, “Chronic Fatigue Syndrome /Myalgic Encephalomyelitis: Characteristics of Responders to Rintatolimod,” Jour Drug Res Dev 2015, 1(1): doi http://dx.doi.org/10/16966/jdrd.103 Irlbeck DM, Vernon SD, Lapp CE, et al., “No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment of the SolveCFS BioBank,” 01 Jan 2014, BMC Research Notes Wells AF, Arnold LM, et al, “Integrating Health Information Technology and Electronic Health Records Into the Management of FM,” Postgrad Med 2013, 125(4): 70-77 Arnold LM, Clauw DJ, Dunegan LJ, Turk DC, et al.,” A framework for fibromyalgia management for primary care providers,” Mayo Clin Proc. 2012 May;87(5):488-96. PMID: 22560527 Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL; Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM, “A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimid in severe cases of chronic fatigue syndrome,” PLoS One. 2012;7(3):e31334. Epub 2012 Mar 14. PMID: 22431963 Jason L, Porter N, Shelleby E, Till L, Bell DS, Lapp CW, Rowe K, De Meirleir K, “Severe versus Moderate criteria for the new pediatric case definition for ME/CFS,” Child Psychiatry Hum Dev. 2009 Dec;40(4):609-20. PMID:19513826 Jason, L., Porter, N., Shelleby, E., Till, L., Bell, D.S., Lapp, C.W., Rowe, K., De Meirleir, K., “Severe versus Moderate criteria for the new pediatric case definition for ME/CFS,” Child Psychiatry Hum Dev. 2009-12-01, PMID: 19513826 Jason LA, Porter N, Shelleby E, Bell DS, Lapp CW, Rowe K, and DeMeirleir K, “A case definition for children with myalgic encephalomyelitis / chronic fatigue syndrome ,” Clinical Medicine: Pediatrics 2008, 1:53-57 http://www.iacfsme.org/Portals/0/pdf/pediatriccasedefinitionshort.pdf Van Hoof E, De Becker P, Lapp C, Cluydts R, De Meirleir K, “Defining the occurrence and influence of alpha-delta sleep in chronic fatigue syndrome,” Am J Med Sci. 2007 Feb;333(2):78-84. PMID:17301585 Van Hoof E, Coomans D, DeBecker P, Lapp C, “Coping in patients with CFS and patients with psychiatric disorders,” J Nerv Ment Dis, 2005 Lapp, CW, “6th International Conference on CFS, FM, & Related Illnesses,” Fibromyalgia Frontiers, Quarterly Journal of the National FM Partnership; 11(1): 2003 Lapp, CW, “CFS versus FM: twins, cousins, or just acquaintances?” Fibromylagia Aware, Sep-Dec 2002; 72-73 Using Antidepressants to Treat CFS, CFIDS Chronicle, Summer 2001 (http://www.cfids.org/archives/2001rr/2001-rr3-article01.asp) Lapp CW, “Childbearing and CFIDS,” CFIDS Chronicle, Summer 2000; 13(3):1-3 Childbearing and Chronic Fatigue Syndrome: Making A Difficult Decision, CFIDS Chronicle, Summer 2000 (www.cfids.org/archives/2000/2000-3-article01.asp) Lapp CW, “The role of laboratory tests in diagnosis of CFS,” CFS Research Review, Winter 2000, 1(1): 6-8 (http://www.cfids.org/archives/2000rr/2000-rr1-article03.asp) Vojdani A, Lapp CW, “Interferon-induced proteins are elevated in blood samples of patients with chemically or virally induced chronic fatigue syndrome,”Immunopharmacol Immunotoxicol. 1999 May;21(2):175-202. PMID: 10319275 “CFIDS and Youth,” pamphlet, CFIDS Association of America, Apr 1999 Lapp CW, “Using Cobalamin for the management of CFS,” CFIDS Chronicle, Nov/Dec 1999; 12(6): 14 Lapp CW et al, “FMS/CFS treatment approaches,” Fibromyalgia Network, Oct 1999; 47:10-13 Vojdani A & Lapp CW, “The relationship between CFS and chemical exposure,”Journal of CFS 1999; 5(3/4):207-221 Alpern HL et alia, American Association of Disability Evaluating Physicians Position Paper on Chronic Fatigue Syndrome, Disability, 1999; 8(2) Vojdani A, Lapp CW, et al., “Interferon-induced proteins are elevated in blood samples of patients with chemically or virally induced CFS,” Immunopharm Immunotoxicol, 1999; 21(2):175-202 Lapp CW, “Epstein-Barr virus common, but varies in severity,” Charlotte News & Observer, May 31, 1999 Using B-12 for the Management of CFS, CFIDS Chronicle, Nov-Dec 1998 (http://www.cfids.org/archives/1999/1999-6-article03.asp) Vojdani A, Choppa PC, Tagle C, Andrin R, Samimi B, Lapp CW, Detection of Mycoplasma genus and Mycoplasma fermentans by PCR in patients with Chronic Fatigue Syndrome, FEMS Immunol Med Microbiol. 1998 Dec; 22(4):355-65. PMID: 9879928 Vojdani A, Choppa PC, Lapp CW, “Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome,” J Clin Lab Immunol. 1998;50(1):1-16. PMID: 10189612 Lapp, CW, “Management of Chronic Fatigue Syndrome in Children,” Journal of Chronic Fatigue Syndrome ,1997; 3(2): 59 Vojdani A, Choppa, Lapp, “Downregulation of RNaseL inhibitor correlates with upregulation of interferon-induced proteins in patients with CFIDS, J.Clin.Lab. Immunol., 1998; 50 (1): 1 Lapp CW and Hyman H, “Diagnosis of Chronic Fatigue Syndrome,” Arch Intern Med, 1997; 157 (Dec 8/22): 2663 PMID: 9531237 Lapp, CW, “Exercise limits in chronic fatigue syndrome”, American Journal of Medicine, 1997; 103:83 PMID: 9236491 Vojdani A, Ghoneum, Choppa, & Lapp, “Elevated Apoptotic cell population in patients with CFS: the pivotal role of protein kinase RNA, Journal of Internal Med, 1997; 242: 465 PMID: 9437407 Lapp CW, “Exercise limits in chronic fatigue syndrome,” 01 Jun 1997, Amer J Med Lapp CW and Cheney PR, “The Chronic Fatigue Syndrome: Case Definition for Practitioners,” Ann IM, 01 Jul 1995; 123 (1): 74 (http://annals.org/article.aspx?articleid=708812) Lapp, CW, “Chronic Fatigue Syndrome Is A Real Disease,” North Carolina Family Physician 43(1), 6-11, Winter 1992 |
| Books Chapters & Booklets | Jason LA and Lapp CW, ed.,” Understanding the Behavioral and Medical Impact of Long COVID,” Routledge Publishing, NY April 2023
Campbell B, Managing Chronic Fatigue Syndrome and Fibromyalgia: Feel Better, Take Charge, Regain Hope, Feb 2016. Major contributor and forward. Available from Amazon and other booksellers. Malott M, How Many Marbles Do You Have? Helping Children Understand the Limitations of Those With Chronic Fatigue Syndrome and Fibromyalgia. Nov 2011. Contributor, editor, forward. ME/CFS Primer for Clinical Practitioners, Sep 2012, www.iacfsme.org/Home/Primer/tabid/509/Default.aspx or www.thebookpatch.com/BookStore.aspx Verillo E, Chronic Fatigue Syndrome: A Treatment Guide, 2nd Ed., Sep 2012 Chapter 10, Protocols, Ebook available on Kindle or Nook Glancy, M, Ed., LexisNexis, section on disability evaluation in Chronic Fatigue Syndrome, Matthew Bender & Sons, NY, 2004 Moss D, McGrady A, Davies TC, Wickramasekera I, Ed., Handbook of Mind-Body Medicine, Sage Publications, Thousand Oaks, CA, 2003, Chapter 24, “Chronic Fatigue Syndrome,” Jason L, Fennel PA, Taylor RR, Ed., Handbook of CFS, Wiley, Hoboken NJ, 2003, Foreword Smith, DM, “Disability Evaluation in a Nutshell,” CFIDS Association of America, Charlotte NC, 2000 “Chronic Fatigue Syndrome: A Diagnostic & Management Challenge,” a learning curriculum developed by C.Lapp, L. Jason, N. Klimas, et alia, for the Chicago AHEC, HRSA, and the CDC. Available online (www.cdc.gov), in print or video format (www.cfids.org),1999-2009 Rigden S, “Chronic Fatigue Syndrome” HealthComm International, Gig Harbor WA, May 1998 |
| Seminars & Webinars | AACFS/IACFS Seminars biannually since 1998 CDC Grand Rounds , lead presenter, February 2016 CDC Patient Webinar (PCOCA), October 2015 World Institute of Pain, Miami, February 2012 MedScape Webinar, January 2012 Pfizer Fibrocollaborative: FM Diagnosis and Management Series, 2008-2012 Pain Society of the Carolinas, October 2011 CFIDS Association Webinar, July 2011 CFIDS Association Webinar, August 2009 MedScape Webinar, October 2008 |
| Lectures | Lecturer on Chronic Fatigue Syndrome and Fibromyalgia to medical and hospital staffs at: Oslo, Norway Auckland and Wellington, New Zealand University of Tokyo, Japan Wisconsin Academy of Family Physicians, Milwaukee, WI Albany Medical College, Albany NY Blodgett Memorial Hospital, Grand Rapids, MI Dorothy Dix Hospital, Raleigh, NC Holly Hill Hospital, Raleigh, NC NC Academy of Family Physicians, Myrtle Beach SC Boca Raton Community Hospital, FL Mental Health Association of Wilson, NC Wheeling Hospital, Wheeling, WV Duke Raleigh Hospital, Raleigh, NC WakeMed Healthcare System, Raleigh, NC Social Security Disability Division, Raleigh NC NC State University, Raleigh, NC University of Connecticut School of Medicine, Hartford, CN Queens College, Charlotte, North Carolina Charlotte Medical Assistants Association Moses Cone Hospital/AHEC, Greensboro, NC Bays Medical Society, Panama City, FL BC/BS of Rochester Community Rounds Series Lehigh Valley Regional Hospital, Allentown, PA Robert Wood Johnson University Hospital, New Brunswick, NJ NC Academy of Pediatrics, Myrtle Beach SC Duke University Medical Center / Integrative Health AADEP, Tucson, Arizona …and many others Presentations to Support Groups in Raleigh, Greensboro, Charlotte, Chapel Hill, Wilmington, Jamestown & Wilson, NC; Milwaukee, WI; Grand Rapids, MI; Los Angeles, CA; Salt Lake City UT; Dallas, TX; San Diego, CA; Albany, NY; Sacramento CA; Chicago IL; Richmond, VA; Boca Raton, FL; Wheeling, WV; Sarasota, FL; Boston, MA; Flint, MI; Lancaster, PA; Dayton, Ohio; Flint, Michigan; Greenville, SC; Rochester, NY; Hartford, CT; Norfolk, VA, Minneapolis, MN, Lexington KY, Edison NJ; Atlanta GA; Nashville TN; Oslo, Norway; New Zealand; Tokyo, Japan,…among others. |
| Websites | drlapp.com TreatCFSFM.org 71,169 visits in 2012, more than 2 million visits since inception. FMmgmt.com >60,000 visits in the first year in 2012 |
Rev Jun 2019